DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
"Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease"
Growing evidence supports the importance of immune processes in Parkinson’s disease (PD). However, there is a need to improve the quality of observational clinical studies investigating the role of immunity in PD. In this context, an expert panel from the COST Action IMMUPARKNET (CA21117) aimed to develop guidance recommendations for conducting optimal immune profiling in PD. Firstly, criteria for inclusion and exclusion of participants, clinical data collection and participant stratification have been considered. Secondly, brain imaging of neuroinflammation has been reviewed. Finally, this review discusses sample collection, handling and storage of biological samples. In conclusion, this document aims to guide the scientific community in the optimal design of immune profiling studies in PD, so that we can generate robust and reliable data to advance our knowledge in this field., This publication is based upon work from COST Action CA21117, The role of IMMUnity in tackling PARKinson’s disease through a Translational NETwork [IMMUPARKNET], supported by COST (European Cooperation in Science and Technology) (www.cost.eu). Laura Muñoz-Delgado is financially supported by the “Juan Rodés” programme (JR23/00016) from the Instituto de Salud Carlos III and receives funding support from the Consejería de Salud y Consumo de la Junta de Andalucía (NEU-0005-2022). Caroline Williams-Grey receives financial support from the NIHR Cambridge Biomedical Research Centre (NIHR203312) and the Cambridge Centre for Parkinson-Plus, and grant funding from the UKRI Medical Research Council (MR/W029235/1), Cure Parkinson’s, Parkinson’s UK, and the Rosetrees Trust. Gaetan Garraux is supported by ‘Fonds Rahier’, University of Liège and Fonds de la Recherche Scientifique (F.R.S.-FNRS) de Belgique. Gaëtan Garraux has also received support for travel or honorarium from AbbVie, Eurogenerics and Zambon. Diego Clemente has received funding support from Instituto de Salud Carlos III (PI18/00357, PI21/00302, PI24/00447, co-funded by the European Union, CIBERNED CB22/05/00016, “INVESTIGO” programme in the frame of the Plan para la Recuperación, Transformación y Resiliencia (European Union Next Generation funds), and EMD Serono R&D Agreement). Ines Figueira is supported by the the ERC—Grant No. 804229; through PeX—2022.02127.PTDC (PERCEPT) and through the R&D unit iNOVA4Health (LISBOA-01-0145-FEDER-007344; UIDB/04462/2020), and LS4FUTURE Associated Laboratory (LA/P/0087/2020).Pablo Mir has received financial support from the Spanish Ministry of Science and Innovation (RTC2019-007150-1), the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (ISCIII-FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704 and PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI-02526, CTS-7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI-0471-2013, PE-0210-2018, PI-0459-2018 and PE-0186-2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896). Pablo Mir has also received support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, AbbVie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. Cristoforo Comi is supported by the AGING PROJECT—Department of Excellence—Università del Piemonte Orientale. Cristoforo Comi has received travel grants for meeting participation from Ecupharma, Bial and Novartis., Peer reviewed
Project:
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) PI18-00357
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI21-00302
,
ISCIII / H2020 PI24
,
EC / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 804229
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII) RTC2019-007150-1
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI16-01575
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI18-01898
,
ISCIII / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII) PI19-01576
,
ISCIII / Plan Estatal de Investigación Científica PI20-00613
,
ISCIII / Técnica y de Innovación 2021-2023 PI21-01875
,
ISCIII PI22-01704
,
ISCIII PI23
DOI: http://hdl.handle.net/10261/406156, https://api.elsevier.com/content/abstract/scopus_id/105019353190
HANDLE: http://hdl.handle.net/10261/406156, https://api.elsevier.com/content/abstract/scopus_id/105019353190